GIP / GLP1 co-agonist compounds

MYPI2026002138A0Undetermined Publication Date: 2020-01-23ELI LILLY & CO
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
MYPI2026002138
Authority / Receiving Office
MY · MY
Patent Type
Applications
Current Assignee / Owner
Priority Date
2018-10-03
Filing Date
2019-07-22
Publication Date
2020-01-23
Patent Text Reader

Abstract

The present invention relates to compounds having activity at both the human glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The present invention also relates to compounds having an extended duration of action at each of these receptors. Furthermore, the present invention relates to compounds that may be administered orally. Compounds may be useful in the treatment of type 2 diabetes mellitus (“T2DM”). Also, the compounds may be useful in the treatment of obesity.
Need to check novelty before this filing date? Find Prior Art